"Weida" Nayan tablet 375 mg (Naproxian) outer box.

(Photo by reporter Wu Liangyi)

[Reporter Wu Liangyi/Taipei Report] The Food and Drug Administration announced today that there are 5 types and 6 batches of "Weida" drugs that need to be recalled due to flaws in the manufacturing process. Drugs such as obstacles.

"Weida"

Nayan Tablets 375 mg (Naproxen) main ingredient is NAPROXEN, indications are osteoarthritis, rheumatoid arthritis, juvenile arthritis, joint adhesive spondylitis, tendonitis, bursitis , and acute gout, primary menstrual pain, relief of mild to moderate pain, a manufacturing batch number "111003" due to defects in the manufacturing process of the batch number product in the case, the manufacturer voluntarily recalled it.

Please read on...

"Weida" Nayan tablets 375 mg.

(Photo by reporter Wu Liangyi)

"Weida

" Yikushi Tablets 500mm (Skrafe) is indicated for duodenal ulcers and gastric ulcers. The manufacturer voluntarily recalled the batch number "224009" due to defects in the manufacturing process.

"Weida" is suitable for 500mm ingots.

(Photo by reporter Wu Liangyi)

"Weida" is suitable for 500mm ingots.

(Photo by reporter Wu Liangyi)

"Weida"

Superab film-coated tablet 500 mg is indicated for respiratory tract infection, otitis media, sinusitis, eye infection, kidney and urinary tract infection (including gonorrhea), abdominal infection (including peritonitis) caused by bacteria sensitive to CIPROFLOXACIN ), skin and soft tissue infections, osteomyelitis, joint infections, bacteremia.

Inhalational anthrax (after exposure) in adults and children.

Complicated urinary tract infection and pyelonephritis caused by Escherichia coli in children (1-17 years), cystic fibrosis associated with Pseudomonas aeruginosa with acute pulmonary exacerbation (5-17 years).

Batch number "210008" needs to be recalled by the manufacturer due to flaws in the manufacturing process.

"Weida" Superab film-coated tablets 500 mg.

(Photo by reporter Wu Liangyi)

Veda Supermax film-coated tablet 500 mg (outer box).

(Photographed by reporter Wu Liangyi)

"Weida" Changxue Lin film-coated tablet

9.6mm (Ginkgo biloba flavonoid glycoside) is indicated for peripheral blood circulation disorders, and the manufacturer has to recall it due to defects in the manufacturing process.

500 mg is indicated for anti-inflammatory and analgesic effects on degenerative arthritis and rheumatoid arthritis, and it also needs to be recalled.

Weida Changxue Lin film-coated ingot 9.6 mm.

(Photo by reporter Wu Liangyi)

Wei Dale Painless Film-Coated Tablets 500mg.

(Photographed by reporter Wu Liangyi)

Wei Dale painless film-coated tablet 500 mg (bottle sticker).

(Photo by reporter Wu Liangyi)

Fu Shuqing, section chief of the Food and Drug Administration, said that this was due to the fact that the pharmaceutical factory added unapproved pharmaceutical processes in the manufacturing process and did not comply with drug GMP regulations, so all of them had to be recalled from the shelves, and a total of 676,000 pills of 5 models and 6 batches had to be recalled. , but these drugs all have alternative drugs of different brands for patients and doctors to choose.

Fu Shuqing said that this is not the first time that the pharmaceutical factory has released a contract. There have been other drugs that had to be withdrawn from the shelves due to the same problem before. It was only discovered after an expanded inventory. The pharmaceutical factory can only resume production after confirming that there are no more process problems.

☆Health news will never be missed, click like to follow the fan page.

☆For more important medical news, please go to Liberty Health.com.

keywords

• gastric medicine

• drug recovery

• pain reliever and anti-inflammatory drug

• drug safety

related news